Barclays lifts target for HealthEquity stock to USD 115.00

Published on 10/20/2026 at 20:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HealthEquity reported USD 350.73 million revenue in its second quarter. HealthEquity stock costs EUR 84.75 on October 20, 2026 at 8:32 p.m. CEST.

Analyst target and results

Barclays raised its HealthEquity target from USD 110.00 to USD 115.00 on September 18, 2026.
Second-quarter revenue reached USD 350.73 million, up 95.50 percent year over year, on July 31, 2026.
HealthEquity stock costs EUR 84.75 at Lang & Schwarz on October 20, 2026 at 8:32 p.m. CEST.
The stock had a USD 7.9 billion market capitalization and a 34.40 price-to-earnings ratio as of October 20, 2026.

HQY, US42226A1079, Illustration mit AI erstellt.

Barclays raised its price target for HealthEquity from USD 110.00 to USD 115.00 while maintaining an Overweight rating in a note dated September 18, 2026, as reported by Yahoo Finance. The stock was trading at EUR 84.75 at Lang & Schwarz on October 20, 2026 at 8:32 p.m. CEST.

Revenue reached USD 350.73 million

HealthEquity reported USD 350.73 million in revenue for the second quarter ended July 31, 2026, compared with USD 325.84 million in the prior-year quarter. That represents a 7.63 percent increase, while net income reached USD 65.64 million, according to MarketBeat. Adjusted earnings per share of USD 1.24 exceeded the USD 1.19 consensus by USD 0.05.

Stock sits within its yearly range

HealthEquity traded between USD 72.76 and USD 107.62 over the 52 weeks through October 20, 2026. Its USD 95.28 Nasdaq price at 2:36 p.m. ET stood 11.47 percent below the 52-week high, while the company had a USD 7.9 billion market capitalization and a 34.40 price-to-earnings ratio.

Target remains above the Nasdaq price

Barclays' USD 115.00 target is 20.69 percent above the USD 95.28 Nasdaq price. A broader survey cited by MarketBeat showed 13 analysts, including 10 Buy ratings, one Strong Buy, one Hold and one Sell, with an average target of USD 112.20.

Peer valuations put scale in view

Comparison with peers

HealthEquity: price-to-earnings ratio 34.40, market capitalization USD 7.9 billion. Paychex (NASDAQ, USD): daily gain 2.00 percent, price-to-earnings ratio 22.46, market capitalization USD 40.2 billion. Automatic Data Processing (NASDAQ, USD): daily gain 1.61 percent, price-to-earnings ratio 26.63, market capitalization USD 115.6 billion.

Price and analyst view

Barclays' target revision gives investors a dated valuation marker, while the second-quarter figures provide an operating comparison. The current euro quotation remains separate from the Nasdaq valuation figures because the two markets use different currencies.

The further course of trading is shown by the continuously updated real-time quote of HealthEquity stock.